Program to Improve Kidney Disease Screening and Treatment in Adults With Type 2 Diabetes
Tests a program for kidney disease care in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
Key facts
- Where
- Ann Arbor, Birmingham, Duluth, Durham, Houston, St. Petersburg, and Temple, United StatesSee the 7 sites
Where in United States
- University of MichiganAnn Arbor, United StatesTaking people
- University of AlabamaBirmingham, United StatesTaking people
- Essentia Institute of Rural HealthDuluth, United StatesTaking people
- Duke UniversityDurham, United StatesTaking people
- Houston MethodistHouston, United StatesTaking people
- Orlando HealthSt. Petersburg, United StatesTaking people
- Baylor Scott & WhiteTemple, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Duke University
- Trial code
- NCT06906640
- Record updated
- 1 October 2026
- Original description
IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.Read full original descriptionShow less
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 2) (IRIS-CKD)
IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Inclusion: (CKD Management); Adults with type 2 diabetes (T2D); Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP); Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment):; UACR >300 mg/g or; eGFR <45 ml/min/1.73 m2 or; UACR ≥30 mg/g with eGFR <60 ml/min/1.73 m2; Receiving <100% GDMT at baseline. For patients with UACR <30 mg/g, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy. For all other eligible patients, GDMT includes ACEi/ARB, SGLT2i, and Finerenone, unless contraindications for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.).
Exclusion: (CKD Management); Type 1 diabetes; Most recent eGFR <20 ml/min/1.73 m2; Prior kidney transplant; Autosomal dominant polycystic kidney disease (ADPKD); Active pregnancy or plans for conception within 1 year.